{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:19:18Z","timestamp":1784089158156,"version":"3.55.0"},"reference-count":68,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FAPESP","award":["2015\/02324-3"],"award-info":[{"award-number":["2015\/02324-3"]}]},{"name":"FAPESP","award":["2018\/00567-4"],"award-info":[{"award-number":["2018\/00567-4"]}]},{"name":"FAPESP","award":["308557\/2018-2"],"award-info":[{"award-number":["308557\/2018-2"]}]},{"name":"FAPESP","award":["310876\/2018-4"],"award-info":[{"award-number":["310876\/2018-4"]}]},{"name":"CNPq","award":["2015\/02324-3"],"award-info":[{"award-number":["2015\/02324-3"]}]},{"name":"CNPq","award":["2018\/00567-4"],"award-info":[{"award-number":["2018\/00567-4"]}]},{"name":"CNPq","award":["308557\/2018-2"],"award-info":[{"award-number":["308557\/2018-2"]}]},{"name":"CNPq","award":["310876\/2018-4"],"award-info":[{"award-number":["310876\/2018-4"]}]},{"name":"UNESP","award":["2015\/02324-3"],"award-info":[{"award-number":["2015\/02324-3"]}]},{"name":"UNESP","award":["2018\/00567-4"],"award-info":[{"award-number":["2018\/00567-4"]}]},{"name":"UNESP","award":["308557\/2018-2"],"award-info":[{"award-number":["308557\/2018-2"]}]},{"name":"UNESP","award":["310876\/2018-4"],"award-info":[{"award-number":["310876\/2018-4"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Clinical trials have shown that sodium glucose co-transporter 2 (SGLT2) inhibitors improve clinical outcomes in diabetes mellitus (DM) patients. As most studies were performed in Type 2 DM, the cardiovascular effects of SGLT2 inhibition still require clarification in Type 1 DM. We analyzed the effects of SGLT2 inhibitor dapagliflozin on cardiac remodeling in rats with streptozotocin-induced diabetes, an experimental model of Type 1 DM. Methods: Male Wistar rats were assigned into four groups: control (C, n = 14); control treated with dapagliflozin (C + DAPA, n = 14); diabetes (DM, n = 20); and diabetes treated with dapagliflozin (DM + DAPA, n = 20) for 8 weeks. Dapagliflozin dosage was 5 mg\/kg\/day. Statistical analyses: ANOVA and Tukey or Kruskal\u2013Wallis and Dunn. Results: DM + DAPA presented decreased blood pressure and glycemia and increased body weight compared to DM (C 507 \u00b1 52; C + DAPA 474 \u00b1 50; DM 381 \u00b1 52 *; DM + DAPA 430 \u00b1 48 # g; * p &lt; 0.05 vs. C; # p &lt; 0.05 vs. C + DAPA and DM + DAPA). DM echocardiogram presented left ventricular and left atrium dilation with impaired systolic and diastolic function. Cardiac changes were attenuated by dapagliflozin. Myocardial hydroxyproline concentration and interstitial collagen fraction did not differ between groups. The expression of Type III collagen was lower in DM and DM + DAPA than their controls. Type I collagen expression and Type I-to-III collagen ratio were lower in DM + DAPA than C + DAPA. DM + DAPA had lower lipid hydroperoxide concentration (C 275 \u00b1 42; C + DAPA 299 \u00b1 50; DM 385 \u00b1 54 *; DM + DAPA 304 \u00b1 40 # nmol\/g tissue; * p &lt; 0.05 vs. C; # p &lt; 0.05 vs. DM) and higher superoxide dismutase and glutathione peroxidase activity than DM. Advanced glycation end products did not differ between groups. Conclusion: Dapagliflozin is safe, increases body weight, decreases glycemia and oxidative stress, and attenuates cardiac remodeling in an experimental rat model of Type 1 diabetes mellitus.<\/jats:p>","DOI":"10.3390\/antiox11050982","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T08:34:29Z","timestamp":1652776469000},"page":"982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus"],"prefix":"10.3390","volume":"11","author":[{"given":"Camila Moreno","family":"Rosa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijon Henrique Salome","family":"Campos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Rafael Abreu","family":"Reyes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Cesar","family":"Damatto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Yamada","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana Urbano","family":"Pagan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Janini","family":"Gomes","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8493-5329","authenticated-orcid":false,"given":"Camila Renata","family":"Corr\u00eaa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-689, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Angelica Henrique","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Institute of Biosciences, Sao Paulo State University, UNESP, Botucatu 18618-970, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Politi","family":"Okoshi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katashi","family":"Okoshi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Botucatu 18618-687, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2022 Update: A report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: Metabolic alterations and therapeutic interventions: A state-of-the-art review from the Translational Research Committee of the Heart Failure Association\u2014European Society of Cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","article-title":"Diabetic cardiomyopathy","volume":"124","author":"Dillmann","year":"2019","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.acvd.2021.08.004","article-title":"The role of hyperglycaemia in the development of diabetic cardiomyopathy","volume":"114","author":"Ernande","year":"2021","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4239\/wjd.v4.i5.177","article-title":"Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management","volume":"4","author":"Pappachan","year":"2013","journal-title":"World J. Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CRD.0b013e318244e57c","article-title":"Advanced glycation end products and diabetic cardiovascular disease","volume":"20","author":"Prasad","year":"2012","journal-title":"Cardiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","article-title":"Empagliflozin limits myocardial infarction in vivo and cell death in vitro: Role of STAT3, mitochondria, and redox aspects","volume":"8","author":"Andreadou","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/2042098614551938","article-title":"Dapagliflozin efficacy and safety: A perspective review","volume":"5","author":"Anderson","year":"2014","journal-title":"Ther. Adv. Drug. Saf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG Outcome Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A State-of-the-art Review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s13300-021-01047-5","article-title":"Effects of sodium glucose co-transporter 2 inhibitors in type 1 diabetes mellitus on body composition and glucose variabilities: Single-arm, exploratory trial","volume":"12","author":"Baba","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: Post-hoc renal analysis of the depict randomised controlled trials","volume":"8","author":"Dandona","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13300-020-00971-2","article-title":"Assessing patient satisfaction following sodium glucose co-transporter 2 inhibitor treatment for type 1 diabetes mellitus: A prospective study in Japan","volume":"12","author":"Ishibashi","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3892\/etm.2021.9813","article-title":"Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials","volume":"21","author":"Huang","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00592-021-01686-x","article-title":"Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials","volume":"58","author":"Rao","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/dom.14556","article-title":"Off-label use of sodium glucose co-transporter inhibitors among adults in type 1 diabetes exchange registry","volume":"24","author":"Hughes","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"154910","DOI":"10.1016\/j.metabol.2021.154910","article-title":"Heart failure in diabetes","volume":"125","author":"Jankauskas","year":"2021","journal-title":"Metabolism"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-016-0442-1","article-title":"Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with diabetes mellitus","volume":"15","author":"Rosa","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"457848","DOI":"10.1155\/2015\/457848","article-title":"Low intensity physical exercise attenuates cardiac remodeling and myocardial oxidative stress and dysfunction in diabetic rats","volume":"2015","author":"Gimenes","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12933-015-0255-7","article-title":"Rutin administration attenuates myocardial dysfunction in diabetic rats","volume":"14","author":"Guimaraes","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-017-0657-9","article-title":"Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced diabetes mellitus","volume":"17","author":"Gimenes","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_25","first-page":"BR367","article-title":"Diet-induced obesity causes metabolic, endocrine and cardiac alterations in spontaneously hypertensive rats","volume":"16","author":"Martinez","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1159\/000354526","article-title":"Aldosterone blockade reduces mortality without changing cardiac remodeling in spontaneously hypertensive rats","volume":"32","author":"Cezar","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000363003","article-title":"Heart failure-induced diaphragm myopathy","volume":"34","author":"Lima","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0002-9629(15)40834-1","article-title":"Myocardial function during chronic food restriction in isolated hypertrophied cardiac muscle","volume":"320","author":"Cicogna","year":"2000","journal-title":"Am. J. Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2011.06.068","article-title":"Critical infarct size to induce ventricular remodeling, cardiac dysfunction and heart failure in rats","volume":"151","author":"Minicucci","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1590\/S0100-879X2004000400019","article-title":"Food restriction induces in vivo ventricular dysfunction in spontaneously hypertensive rats without impairment of in vitro myocardial contractility","volume":"37","author":"Okoshi","year":"2004","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1111\/jcmm.15191","article-title":"Effects of aerobic and resistance exercise on cardiac remodelling and skeletal muscle oxidative stress of infarcted rats","volume":"24","author":"Gomes","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1159\/000486115","article-title":"N-acetylcysteine influence on oxidative stress and cardiac remodeling in rats during transition from compensated left ventricular hypertrophy to heart failure","volume":"44","author":"Reyes","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1590\/S0100-879X1997000900013","article-title":"Myocyte necrosis is the basis for fibrosis in renovascular hypertensive rats","volume":"30","author":"Okoshi","year":"1997","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijcard.2016.07.072","article-title":"Effects of late exercise on cardiac remodeling and myocardial calcium handling proteins in rats with moderate and large size myocardial infarction","volume":"221","author":"Guizoni","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1139\/y97-163","article-title":"Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats","volume":"75","author":"Matsubara","year":"1997","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijcard.2016.04.101","article-title":"Myocardial myostatin in spontaneously hypertensive rats with heart failure","volume":"215","author":"Damatto","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000445631","article-title":"Modulation of MAPK and NF-KB signaling pathways by antioxidant therapy in skeletal muscle of heart failure rats","volume":"39","author":"Martinez","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000369683","article-title":"Influence of N-acetylcysteine on oxidative stress in slow-twitch soleus muscle of heart failure rats","volume":"35","author":"Martinez","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jcmm.14025","article-title":"Exercise during transition from compensated left ventricular hypertrophy to heart failure in aortic stenosis rats","volume":"23","author":"Reyes","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01270580","article-title":"Protection of the ischemic diabetic heart by L-propionylcarnitine therapy","volume":"116","author":"Paulson","year":"1992","journal-title":"Mol. Cell. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1042\/bj3060759","article-title":"Decrease in cardiac phosphatidylglycerol in streptozotocin-induced diabetic rats does not affect cardiolipin biosynthesis: Evidence for distinct pools of phosphatidylglycerol in the heart","volume":"306","author":"Hatch","year":"1995","journal-title":"Biochem. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s001250050567","article-title":"Effects of Ginkgo biloba extract and preconditioning on the diabetic rat myocardium","volume":"39","author":"Tosaki","year":"1996","journal-title":"Diabetologia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1139\/cjpp-2020-0572","article-title":"The tyrosine kinase inhibitor crizotinib influences blood glucose and mRNA expression of GLUT4 and PPARs in the heart of rats with experimental diabetes","volume":"99","author":"Hadova","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"403291","DOI":"10.1155\/2015\/403291","article-title":"Cardioprotective activity of Pongamia pinnata in streptozotocin-nicotinamide induced diabetic rats","volume":"2015","author":"Badole","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_45","first-page":"1115","article-title":"Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic\/reperfused hearts","volume":"275","author":"Tosaki","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jat.2550150508","article-title":"Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats","volume":"15","author":"Ewis","year":"1995","journal-title":"J. Appl. Toxicol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1475-2840-12-152","article-title":"Diabetes mellitus activated fetal gene program and intensifies cardiac remodeling and oxidative stress in aged spontaneously hypertensive rats","volume":"12","author":"Rosa","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1590\/S0100-879X2009000200008","article-title":"Streptozotocin-induced mechanical hypernociception is not dependent on hyperglycemia","volume":"42","author":"Cunha","year":"2009","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1292\/jvms.69.969","article-title":"Streptozotocin-induced diabetes increases apoptosis through JNK phosphorylation and Bax activation in rat testes","volume":"69","author":"Koh","year":"2007","journal-title":"J. Vet. Med. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/dom.14620","article-title":"Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German\/Austrian DPV Registry: Improved HbA1c without diabetic ketoacidosis","volume":"24","author":"Seufert","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108462","DOI":"10.1016\/j.diabres.2020.108462","article-title":"The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes","volume":"170","author":"Gillard","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jcsm.12814","article-title":"Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db\/db mice","volume":"13","author":"Bamba","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-018-0943-5","article-title":"SGLT2 inhibitors and mechanisms of hypertension","volume":"20","author":"Briasoulis","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kawasoe, S., Maruguchi, Y., Kajiya, S., Uenomachi, H., Miyata, M., Kawasoe, M., Kubozono, T., and Ohishi, M. (2017). Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol. Toxicol., 18.","DOI":"10.1186\/s40360-017-0125-x"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: Mechanisms of action in heart failure","volume":"107","author":"Joshi","year":"2021","journal-title":"Heart"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Marchini, G.S., Cestari, I.N., Salemi, V.M.C., Irigoyen, M.C., Arnold, A., Kakoi, A., Rocon, C., Aiello, V.D., and Cestari, I.A. (2020). Early changes in myocyte contractility and cardiac function in streptozotocin-induced type 1 diabetes in rats. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237305"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1755-1536-5-15","article-title":"Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease","volume":"5","author":"Fan","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1111\/jcmm.14530","article-title":"Low-intensity aerobic exercise improves cardiac remodelling of adult spontaneously hypertensive rats","volume":"23","author":"Pagan","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.3390\/ijms21082852","article-title":"Can we prevent mitochondrial dysfunction and diabetic cardiomyopathy in type 1 diabetes mellitus? Pathophysiology and treatment options","volume":"21","author":"Cieluch","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10741-017-9663-y","article-title":"Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart","volume":"23","author":"Singh","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.freeradbiomed.2020.11.033","article-title":"Temporal evolution of cardiac mitochondrial dysfunction in a type 1 diabetes model. Mitochondrial complex I impairment, and H2O2 and NO productions as early subcellular events.","volume":"162","author":"Rey","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00239","DOI":"10.1002\/prp2.239","article-title":"Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice","volume":"4","author":"Hatanaka","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1292\/jvms.19-0450","article-title":"Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes","volume":"82","author":"Sayed","year":"2020","journal-title":"J. Vet. Med. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11892-013-0453-1","article-title":"Advanced glycation end products (AGE) and diabetes: Cause, effect, or both?","volume":"14","author":"Vlassara","year":"2014","journal-title":"Curr. Diab. Rep."}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/11\/5\/982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:13:30Z","timestamp":1760138010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/11\/5\/982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["antiox11050982"],"URL":"https:\/\/doi.org\/10.3390\/antiox11050982","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]}}}